Introduction
============

Osteoporotic fractures mainly occur in older persons worldwide. In Italy, 90,000 hip fractures per year affect persons aged older than 50 years, with a growing trend coincident with aging of the population.[@b1-cia-10-1035] In the USA, 90% of 350,000 hip fractures per year occur in persons over 65 years.[@b2-cia-10-1035] Western countries have generally reported increases in hip fracture incidence through the second half of the last century. Hip fracture rates have stabilized over the last 2 decades, with age-adjusted decreases being observed in some centers.[@b3-cia-10-1035]

A fragility fracture at the hip is devastating and is associated with increased morbidity, disability, and mortality.[@b4-cia-10-1035] Epidemiological studies show an annual mortality rate over 25% and incomplete recovery of pre-fracture mobility in more than 50% of survivors.[@b5-cia-10-1035]--[@b7-cia-10-1035] Approximately 60% of hip-fractured patients require assistance with activities of daily living, and 10%--20% of these patients are admitted to care homes in the year following the event.[@b8-cia-10-1035] Hip fracture is also a strong risk factor for future vertebral and non-vertebral fractures. Patients who suffer a hip fracture are two to four times as likely to have a further hip fracture, with 10% having another fracture within 1 year.[@b9-cia-10-1035] Approximately 35% of patients hospitalized for a fragility fracture have a higher risk of being readmitted, with a further fragility fracture within 1--2 years of the previous one.[@b10-cia-10-1035] The economic burden associated with direct costs (including acute in-hospital treatment, post-operative complications, rehabilitation programs and the use of the health services) has been estimated to be \$20 billion in the USA and €30 billion in the European Union. An additional burden is attributable to indirect costs (including burden for family members and caregivers due to the onset or increased disabilities) of hip fractures that have been only partially evaluated and weigh heavily on health care systems.[@b11-cia-10-1035],[@b12-cia-10-1035] Although guideline-recommended osteoporosis treatments can dramatically reduce fracture risk by up to 50%, about 50% of osteoporotic women and 90% of men with incident fragility fracture are not treated with any anti-fracture medication.[@b13-cia-10-1035]--[@b17-cia-10-1035] Further, less than 25% of older patients who sustain fractures receive adequate vitamin D supplementation.[@b18-cia-10-1035],[@b19-cia-10-1035]

In this scenario, fracture liaison services (FLS) have been developed in many health systems to identify persons at high risk for fragility fractures and/or to encourage outpatient primary care physicians to initiate appropriate treatment.[@b20-cia-10-1035]--[@b22-cia-10-1035] Epidemiological studies shown that these services may narrow the care gap for patients with fragility fractures, and they are clinically effective and cost-effective in providing secondary preventive care.[@b23-cia-10-1035] Since FLS have not been widely adopted, mainly due to staff and service reorganization, no improvement in the osteoporotic care gap has been identified in recent years.[@b24-cia-10-1035],[@b25-cia-10-1035] The Fracture Prevention Service (FPS) is a multidisciplinary model of care tailored to identify, assess, and treat in an effective and timely manner all patients who suffer a hip fracture and are at high risk of subsequent fracture. In our experience, FPS was developed by optimizing available resources through a structured path that includes involvement of general practitioners, orthopedic surgeons, and other specialists involved in the treatment of osteoporosis.

The aim of this study was to evaluate the feasibility of the FPS and to estimate the association between implementation of the FPS and outcome measures related to secondary prevention of fragility fractures, including bone mineral density (BMD) testing, evaluation at a fall and fracture clinic, drug prescription, and adherence to pharmacological treatment. The FPS was adapted to address the needs of specific patient populations and it resembles the model of FLS that is currently considered to be the most effective for management of hip-fractured persons.[@b26-cia-10-1035] We believe that given the importance of hip fracture to the Italian health system and its impact on the quality of life of elderly people, building an FPS as in other countries is a mandatory objective.

Materials and methods
=====================

Study design and sample
-----------------------

The FPS is a multidisciplinary and collaborative team, including orthopedic surgeons, geriatricians, physical therapists, nurses, and general practitioners, which assumes responsibility for secondary fracture prevention. The FPS assures case finding, assessment, and diagnostic evaluation, and encourages outpatient primary care physicians to initiate appropriate treatment. During the period April-- December 2011, geriatricians, as providers of a fall and fracture clinic, met with orthopedic surgeons, nurses, physical therapists, and primary care physicians to determine the needs and preferences of these groups for collaboration in order to assure the secondary prevention of fragility fractures. The fall and fracture clinic is a hospital-based outpatient ambulatory service provided jointly by a geriatrician and a physiotherapist. Teaching and training activities were undertaken for staff involved in the FPS to raise awareness concerning guidelines for the diagnosis and treatment of osteoporosis. A fragility fracture protocol was established, and written guidelines for assessment and treatment of persons with a proximal hip fracture were defined for staff in the orthopedic and traumatology department. In detail, low trauma hip fracture is defined as a fracture sustained as a result of a fall from standing height or less and not occurring as a consequence of a road traffic accident. All persons aged 65 years and older admitted with low trauma hip fracture are identified by the orthopedic surgeons and sent the fragility fracture protocol. The protocol includes BMD and blood testing, assessment of fracture risk, and prescription and monitoring of antiosteoporotic treatment. At discharge, the FPS team members send a letter to the general practitioner explaining that their patient is scheduled for a comprehensive fracture and falls risk assessment, including BMD evaluation and blood tests. The main reason for a FPS in our teaching hospital is the large number of surgical procedures done for proximal femoral fracture (n=700 in 2010) in the orthopedics and traumatology department.

In this study, we examined the data gathered from patients with proximal hip fracture admitted to the orthopedics and traumatology department of the teaching hospital at Perugia from October 2010 to March 2011 and from January to June 2012, respectively, before and after implementation of the multidisciplinary and collaborative FPS team. For the purposes of the study, all participants received 6-month and 12-month telephone follow-up by two trained nurses. The study protocol complied with the Declaration of Helsinki and was approved by the ethics committee of the regional health care system.

Demographic, clinical, and treatment-related characteristics
------------------------------------------------------------

We collected demographic data and information concerning the type of surgery used to treat the hip fracture, along with the type and site of previous fragility fractures, by reviewing the clinical charts of patients with proximal hip fracture. The type of hip fracture was classified as femoral neck, subtrochanteric, periprosthetic, or subtrochanteric. Previous fragility fracture sites were classified as hip, vertebral, wrist, and other. Information was collected on instrumental evaluation, based on BMD testing and drug therapy for osteoporosis, ie, calcium ± vitamin D supplementation and bisphosphonates or other agents ongoing before admission and/or recommended at discharge from the orthopedic ward. In addition, first level blood testing for secondary osteoporosis, including calcium, phosphorus, and plasma intact parathyroid hormone were collected when evaluated during the hospital stay. All participants received telephone follow-up with the aim of obtaining information about drug adherence or, where appropriate reasons for suspension, occurrence of falls, fractures, major clinical events requiring hospitalization, and/or mortality. Participants' vital status was determined by telephone follow-up, correspondence, and searches of the Regional Death Index (updated in December 2013).

Statistical analysis
--------------------

Participants' characteristics were described according to their pre-intervention (group A) or post-intervention (group B) enrollment status. Continuous variables with a symmetric distribution were reported as the mean and standard deviation, while those with an asymmetric distribution were summarized as the median and interquartile range. Categorical variables were summarized as proportions and percentages. Statistical comparisons across groups were performed using the Fisher's Exact test, *t*-test, or chi-square test, as appropriate, and sensitivity analysis was performed using McNemar's test. The significance level used for two-sided tests was *P*\<0.05. The probability of patients receiving a specific antifracture drug prescription at hospital discharge as well as their 1-year adherence to prescribed drugs were compared post-FPS versus pre-FPS using multivariate regression based on a generalized linear model procedure ([Tables 1](#t1-cia-10-1035){ref-type="table"} and [2](#t2-cia-10-1035){ref-type="table"}, respectively). Parsimonious models were identified using the stepwise selection method within "proc reg" procedures. All analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

[Table 3](#t3-cia-10-1035){ref-type="table"} shows the characteristics of the participants grouped according to their enrollment phase, ie, before (group A) or after (group B) activation of the FPS, and stratified according to the time of evaluation during their hospital stay, ie, at hospital admission or discharge. Overall, 382 hip-fractured older persons were enrolled in the study, comprising 172 in the 6 months before (group A) and 210 in the 6 months after (group B) activation of the FPS. The majority of participants were women (78.49% versus 71.90%, *P*=0.1400) and aged over 80 years (83.32±8.16 versus 83.52±7.47, *P*=0.8090). In both groups, the most prevalent proximal femoral fractures were at the femoral neck (49.42% versus 42.38%, respectively) and subtrochanteric (45.93% versus 53.81%) sites. Sixty percent of hip-fractured patients underwent an osteosynthesis procedure (59.88% versus 64.76% in the pre-intervention group and post-intervention group, respectively) and about one-third underwent a prosthetic replacement, ie, total arthroplasty or bipolar hip prosthesis (39.53% versus 34.76%). Overall, one of every three patients had already experienced a fragility fracture, with the hip being the most prevalent site (53.97% versus 36.00%), followed by the wrist (14.29% versus 13.33%) and vertebrae (12.70% versus 16.00%). Less than 10% of patients were on antiosteoporosis drug treatment (10.47% versus 7.14%, *P*=0.2502) and/or vitamin D ± calcium supplementation (11.05% versus 5.24%, *P*=0.0358) at admission. Few persons (1.74% versus 0.48%) reported having BMD testing in the years before their fracture. Compared with group A, participants enrolled after activation of the FPS (group B) had a higher probability of receiving recommendations for secondary prevention of fracture at discharge. About half of them were prescribed specific drug treatment (48.51% versus 17.16%, *P*\<0.0001) and calcium ± vitamin D supplementation (50.00% versus 16.57%, *P*\<0.0001), and obtained indications for BMD testing (47.62% versus 14.53%, *P*\<0.0001) and evaluation of fall and fracture risk (52.48% versus 2.37%, *P*\<0.0001) within 3 months of discharge. Bisphosphonates were the most commonly prescribed drugs for secondary fracture prevention at discharge. Almost all hip-fractured patients in group B (98.00%) received calcium and vitamin D supplementation at discharge compared with 66.66% of those in group A. Almost all the characteristics of participants discharged after activation of the FPS were significantly different from those of patients discharged before the intervention ([Table 3](#t3-cia-10-1035){ref-type="table"}). Further, activation of the FPS was associated with the prescription of a complete treatment for secondary fracture prevention at hospital discharge, ie, a specific drug plus calcium and vitamin D supplementation, independent of age, sex, history of fracture, and ongoing drug treatment at admission ([Table 1](#t1-cia-10-1035){ref-type="table"}). No interaction term between antifracture treatment at admission and FPS was found in the model. [Table 4](#t4-cia-10-1035){ref-type="table"} shows 1-year adherence to prescriptions given to patients at hospital discharge and still active in follow-up (n=116 \[67.44%\] of those enrolled in group A and n=142 \[67.61%\] of those enrolled in group B). Of note, 15.7% (n=33) and 12.7% (n=22) of the participants died within 1 year of follow-up, while 16.6% (n=35) and 19.7% (n=34) dropped out for other reasons from group B (post-intervention) and group A (pre-intervention), respectively.

Of note, 15.7% (n=33) and 12.7% (n=22) of the participants died within the 1-year follow-up, while 16.6% (n=35) and 19.7% (n=34) dropped out for other reasons from group B (post-intervention) and group A (pre-intervention), respectively.

Compared with patients in group A, those enrolled after FPS activation (group B) had higher adherence to BMD testing (19.64% versus 50.43%, *P*\<0.0001), fall and fracture clinic evaluation (4.50% versus 64.41%, *P*\<0.0001), and persisted on antiosteoporosis drugs (14.04% versus 44.07%, *P*\<0.0001) and calcium plus vitamin D supplementation (8.26% versus 53.51%, *P*\<0.0001, [Table 4](#t4-cia-10-1035){ref-type="table"}). Independent of age, sex, history of fracture, and ongoing drug treatments at admission, activation of the FPS was positively associated with 1-year adherence to complete pharmacological treatment, ie, an antiosteoporosis drug plus vitamin D and calcium supplementation, for secondary prevention of fragility fractures ([Table 2](#t2-cia-10-1035){ref-type="table"}). No interaction term was found between activation of the FPS and history of specific treatment.

Discussion
==========

Activation of the FPS, a multidisciplinary integrated model of care for secondary prevention of fragility fractures, is an effective strategy for increasing the probability that older adults at the highest risk of a subsequent fragility fracture receive BMD testing, fall and fracture risk assessment, antifracture medications, and for improving 1-year adherence to treatment. In our experience, the FPS resembles a coordinator-based system with an osteoporosis care manager, ie, a geriatrician or orthopedic surgeon, to explain the need for a secondary prevention fracture program to older persons, their relatives, and/or general practitioner, and with a dedicated nurse available to contact and organize access to the outpatient clinic for completing the diagnostic and therapeutic pathway.

Several models of FLS have been developed depending on the setting, target population, health care providers, and the characteristics of specific health care systems.[@b27-cia-10-1035],[@b28-cia-10-1035] Direct comparisons among models of FLS are not feasible because they were developed according to a different health care system organization depending on the countries. In fact, drawing conclusions on the efficacy of a given model should be done considering the existing resources, the actual local organization, and the priorities of the health care system. Compared with previous studies, we confirmed a trend toward a higher success rate of coordinated systems for secondary prevention in hip fracture patients. Although the design of the study was an observational pre-/post-intervention, the rates of therapeutic and diagnostic antifracture recommendations markedly increased at discharge and were of similar magnitude to those in previous randomized controlled trials[@b29-cia-10-1035]--[@b31-cia-10-1035] and studies with a similar design.[@b32-cia-10-1035],[@b33-cia-10-1035] At hospital discharge, one in two of our patients received appropriate management, including BMD testing, fall and fracture risk evaluation, and antifracture drug treatment. In addition, we showed significantly increased adherence 1 year after the hip fracture: Fifty-two percent of the participants still active in follow-up attended the fall and fracture clinic, 43% did the BMD testing, and approximately 40% were on specific antifracture drug treatment. We acknowledge that still a large proportion of participants desire indications for antifracture drug treatments, both at discharge as well as 1-year after fracture. Several factors are involved in the processes associated with improvement of such outcomes; some are related to the organizational aspects of the multidisciplinary team, but others are due to a limited understanding of the deleterious consequences of fractures on the part of patients and their carers. Several lines of evidence suggest that bone-protecting treatments reduce adverse outcomes and the incidence of subsequent fracture without prior dual-energy X-ray absorptiometry scanning,[@b15-cia-10-1035] although there is some controversy about the need for BMD scanning before starting secondary prevention.

An important aspect of this study is that it describes the first coordinator-based program to include an integrated approach for fall and fracture prevention in more than one half of participants attending an outpatient clinic. However, the effects of such a fall prevention program on fracture risk still needs to be clarified in this study sample. Another key element contributing to the success of this program is that it promoted a high level of adherence to medications by proactively monitoring patients over time. The improvement of 1-year drug adherence in our study is an unique finding that was not investigated in previous randomized trials, nor in observational studies with a similar design. In addition, our model of FPS was designed to capture, evaluate, and treat the highest fracture risk stratum of the population. Hip-fractured patients are particularly difficult to bring back to the FPS because of mobility and frailty issues. In our study, the FPS was structured as a multidisciplinary path, integrating available services and specialists within the hospital, to whom hip-fractured patients are automatically referred at the time they are hospitalized. Thus, activation of an appropriate secondary fracture prevention protocol would no longer depend exclusively on the attending physician in the surgical (orthopedic) department, nor the patients should be more committed to looking for secondary fracture prevention after hospital discharge. Ultimately, a key factor in maximizing the beneficial effects of FPS was the involvement of the primary care physicians who contribute to begin therapy as well as monitor the continuity of care. Poor adherence with medications for chronic diseases is a common problem in many patients, especially among older persons with inadequate understanding of their diseases and the detrimental impact on the functionality. Involvement of geriatricians in the FPS overcomes several issues related to choice of treatment, management of comorbidities such as cognitive disorders, depression and chronic disease, polypharmacy, patient's life expectancy, and preference. Coordinated interaction of the different professional disciplines involved, ie, geriatrician, orthopedic surgeon, nurse specialist, physiatrist, and general practitioner, and better comprehension of the risks associated with subsequent fragility fractures on the part of patients and their cares, might have contributed to the improved adherence to pharmacological treatment seen in our study. The good compliance with antifracture treatment (more than 50% in 1 year) may also be ascribed to a more tailored choice of antifracture drugs. This may be considered a good result and represents an important and encouraging outcome of such intervention. Ultimately, the communication and the comprehension of the issues associated with fragility fractures improved among the older adults and their caregivers. Possible reasons for the higher compliance with antifracture treatment after activation of the FPS might be ascribed to a more tailored choice of antifracture drugs and improved comprehension of the risks associated with subsequent fragility fractures.

Several studies from Australia, Canada, France, Ireland, Spain, the Netherlands, the UK, and the USA have described the structure and performance of FLS protocols. The optimal way to organize and deliver an FLS has been the subject of ongoing debate among service leaders and the focus of several systematic reviews.[@b20-cia-10-1035]--[@b22-cia-10-1035],[@b27-cia-10-1035],[@b28-cia-10-1035],[@b34-cia-10-1035]--[@b40-cia-10-1035] The most recent review suggests that only type A, ie, an all-encompassing service where patients with fragility fracture are identified, assessed, and treated for osteoporosis with a fracture liaison coordinator being central to the service, has demonstrated a significant reduction on the incidence of refracture. Our findings are consistent with these reports.[@b25-cia-10-1035]

Availability of a centralized database and a tracking system helps provide the appropriate diagnostic and therapeutic protocol. Therefore, funding the information technology area might ultimately be cost-saving. However, in our experience, competing priorities for nursing time led to suboptimal data entry and difficulties in patients tracking, confirming the importance of identifying dedicated staff. The main problems are not medical but logistic, and the answers to these issues may lie in organizational aspects. Overcoming these issues is a priority since the spread of systematic refracture prevention programs in Italy and elsewhere should be given priority.

We acknowledge that our study has some limitations. Our evaluation of long-term adherence to antifracture drug prescriptions and diagnostic recommendations is limited to 67% of the original sample, mainly because of the high mortality rate (13%--16%) and dropout rate (12%--15%) in the study population. The main reasons for dropout were change of address, unwillingness to be interviewed, deterioration of health status, and onset of severe disability. Further, our participants with hip fracture did not undergo a comprehensive geriatric evaluation during their hospital stay in the orthopedic ward. Therefore, clinical and function-related variables that may affect the outcomes of FPS were not included in the analyses. Ultimately, this is a "before and after" study that relies on historical controls (before and after the period that the FPS was in effect), and not a randomized controlled trial. Because this study simply observed a change in the number of participants that received specific antifracture recommendations, there is always the chance that the change we observed was due to some unobserved confounding variable or systematic bias.

In conclusion, the FPS program improved the care of patients with fragility fractures and positively impacted the cultural communication and education of health care providers. By identifying and addressing the needs of older adults at highest risk for fragility fractures, the FPS is expected to have long-term health and economic benefits for both patients and the community. We believe that development of the FPS is effective for narrowing the deficit of care that exists in the management of patients with fragility fractures, and it is a priority for health care systems worldwide.
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###### 

Multivariate analysis of the association between activation of the Fracture Prevention Service and pharmacological treatment for secondary prevention of fragility fractures at hospital discharge

                                    Pharmacological secondary prevention           
  --------------------------------- -------------------------------------- ------- ----------
  Fracture unit                     0.34                                   0.04    \<0.0001
  Age                               −0.001                                 0.002   0.6875
  Female sex                        0.14                                   0.05    0.0044
  Specific treatment at admission   0.44                                   0.07    \<0.0001
  History of fracture               −0.13                                  0.04    0.0051

**Abbreviation:** SE, standard error.

###### 

Multivariate analysis of the association between implementation of the Fracture Prevention Service and 1-year adherence to pharmacological treatment for secondary prevention of fragility fracture

                  One-year adherence to secondary prevention           
  --------------- -------------------------------------------- ------- ----------
  Fracture unit   0.19                                         0.03    \<0.0001
  Age             −0.001                                       0.002   0.4864
  Female sex      0.09                                         0.03    0.0154

**Notes:** Further confounders, including history of fracture, type of fracture, destination at discharge, history of specific treatment, and calcium and/or vitamin D supplementation at hospital admission were tested and excluded from the parsimonious model using stepwise regression method analysis.

**Abbreviation:** SE, standard error.

###### 

Characteristics of participants enrolled before (group A) and after (group B) activation of the Fracture Prevention Service according to time of hospital assessment (at admission and at discharge, respectively)

                                                     Group A (n=172)   Group B (n=210)   *P*-value
  -------------------------------------------------- ----------------- ----------------- -----------
  Women, n (%)                                       135 (78.49)       151 (71.90)       0.1400
  Age, years, mean ± SD                              83.32±8.16        83.52±7.47        0.8090
  **Clinical characteristics**                                                           
  Type of fracture, n (%)                                                                0.4488
  Femoral neck                                       85 (49.42)        89 (42.38)        
  -- Trochanteric                                    79 (45.93)        113 (53.81)       
  -- Periprosthetic                                  2 (1.16)          3 (1.43)          
  -- Subtrochanteric                                 6 (3.49)          5 (2.38)          
  Type of surgery, n (%)                                                                 0.6178
  -- Osteosynthesis                                  103 (59.88)       137 (64.76)       
  -- Prosthesis                                      68 (39.53)        73 (34.76)        
  Previous fracture, n (%)                           64 (37.21)        75 (35.71)        0.7625
  Previous fracture site, n (%)                                                          0.1210
  -- Femur                                           34 (53.97)        27 (36.00)        
  -- Vertebra                                        8 (12.70)         12 (16.00)        
  -- Wrist                                           9 (14.29)         10 (13.33)        
  -- Other                                           12 (19.05)        26 (34.66)        
  **Diagnostic and therapy before index fracture**                                       
  BMD testing, n (%)                                 3 (1.74)          1 (0.48)          0.2258
  Antiosteoporosis drug treatment, n (%)             18 (10.47)        15 (7.14)         0.2502
  Calcium and/or vitamin D supplementation, n (%)    19 (11.05)        11 (5.24)         0.0358
  **Diagnostic and therapy after index fracture**                                        
  BMD testing, n (%)                                 25 (14.53)        100 (47.62)       \<0.0001
  Fall and fractures clinic evaluation, n (%)        4 (2.37)          106 (52.48)       \<0.0001
  Antiosteoporosis drug treatment, n (%)             29 (17.16)        98 (48.51)        \<0.0001
  Calcium/vitamin D supplementation, n (%)           28 (16.57)        101 (50.00)       \<0.0001

**Note:** *P*-value from Fisher's Exact test, *t*-test, or chi-square test, as appropriate.

**Abbreviations:** BMD, bone mineral density; SD, standard deviation.

###### 

One-year adherence to recommendations prescribed at discharge among participants enrolled before (group A) and after (group B) implementation of the Fracture Prevention Service

                                                         Group A       Group B       *P*-value
  ------------------------------------------------------ ------------- ------------- -----------
  Participants contributing to baseline, n (%)           172 (100%)    210 (100%)    --
  One-year mortality, n (%)                              22 (12.7)     33 (15.7)     0.5011
  One-year dropout, n (%)                                34 (19.76)    35 (16.66)    0.4332
  Participants contributing to 1-year follow-up, n (%)   116 (67.44)   142 (67.61)   0.1655
  BMD testing, n (%)                                     24 (20.68)    62 (43.66)    \<0.0001
  Fall and fracture clinic attendance, n (%)             6 (5.17)      78 (54.92)    \<0.0001
  Specific antifracture drug therapy, n (%)              17 (14.65)    56 (39.43)    \<0.0001
  Calcium plus vitamin D supplementation, n (%)          10 (8.62)     65 (45.77)    \<0.0001

**Note:** *P*-value from Fisher's Exact test, *t*-test, or chi-square test, as appropriate.

**Abbreviation:** BMD, bone mineral density.
